Anti-Human CD279 (PD-1) (Nivolumab) - APC

Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance.

PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity.

PD-L1 and PD-L2 are the two ligands known to bind PD-1.

PD-L1 has increased expression in several cancers.1 PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines.

Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.2 Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands.3 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.4 This cost-effective, research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects.